Biopharmaceutical News and Research

RSS

Sartorius launches the Octet® R8e System: Real-time, label-free biomolecular interaction analysis with unprecedented sensitivity and efficiency

The life science group Sartorius launches the new Octet® R8e biolayer interferometry (BLI) system, providing researchers with its most advanced detection capabilities to date for real-time, high-throughput analysis of protein-protein, protein-small molecule, and other biomolecular interactions.

24 May 2025

How innovation in dried blood spot testing is transforming neurological disease monitoring

In this interview, NewsMedical speaks with Quanterix about blood spot testing for neurological applications.

From Quanterix 21 May 2025

Astoriom expands global footprint for sample stability storage services

Astoriom, a global leader in the R&D sample stability and biorepository storage industry, today announced that it has expanded the stability storage capabilities at its Tramore site in Ireland to meet demand for scalable, flexible, regulatory-compliant storage solutions from -60 °C to -196 °C and ICH (International Council for Harmonisation) temperature-controlled stability conditions.

20 May 2025

Trump exaggerates speed and certainty of prescription drug price reductions

President Donald Trump expressed high hopes for an executive order to reduce drug prices.

20 May 2025

Once-daily oral treatment shows positive results in first human study for obesity treatment

A first-in-human study of an investigational once-daily oral treatment for obesity (SYNT-101) demonstrated positive preliminary data for the safe and effective redirection of nutrient absorption into the lower intestine, the weight loss and metabolic management mechanism behind gastric bypass surgery.

14 May 2025

PhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced Barbara Duncan has joined its Board as Chair, and Stephen Dilly as Non-Executive Director.

From PhoreMost 12 May 2025

Waters integrates Multi-Angle Light Scattering Detectors with empower software for improved biologics quality control and simplified regulatory compliance

Waters Corporation today announced that its Empower™ Software now supports biologics data acquisition and quality control (QC) analysis from Multi-Angle Light Scattering (MALS) and differential Refractive Index (RI) instruments in its Wyatt Technology™ Portfolio.

From Waters Corporation 7 May 2025

Arc Institute expands virtual cell atlas with industry partnerships

Arc Institute continues its work to generate and share large-scale, high-quality datasets of cell state before and after chemical or genetic perturbations to enable "virtual cell" models and other innovations.

28 Apr 2025

Medicare changes set to lower out-of-pocket costs for cancer medications

Even for patients covered by Medicare, annual out-of-pocket costs for lifesaving cancer treatments taken in pill form have often exceeded $10,000-until recently.

28 Apr 2025

New Medicare changes ease cost burden for cancer drugs

Even for patients covered by Medicare, annual out-of-pocket costs for lifesaving cancer treatments taken in pill form have often exceeded $10,000-until recently.

25 Apr 2025

Insights into Raman spectroscopy as a bioprocess analytical technique

Dr. Nimesh Khadka discusses Raman spectroscopy's role in bioprocess monitoring, highlighting its advantages in molecular specificity and real-time analysis.

From Thermo Fisher Scientific – Pharmaceutical and Biopharmaceutical Solutions 23 Apr 2025

Boost your transfection success with these proven expert tips

Gain expert insights in this interview on achieving transfection success. Explore proven strategies to optimize your approach and enhance results.

From Sartorius 22 Apr 2025

Source Bioscience acquires Cambridge Clinical Laboratories

Source BioScience UK Ltd, an industry-leading provider of genomic services and histopathology diagnostics, today announced it had completed the acquisition of Cambridge Clinical Laboratories (CCL), a leading Cambridge-based provider of clinical, personalized healthcare testing services.

10 Apr 2025

New drug compound prevents long COVID symptoms in mice

Researchers have shown a new drug compound can prevent long COVID symptoms in mice – a landmark finding that could lead to a future treatment for the debilitating condition.

8 Apr 2025

New drug strategy targets Staphylococcus aureus toxin to treat pneumonia

Pneumonia caused by the bacterium Staphylococcus aureus is one of the most dangerous infections that can occur in hospital.

2 Apr 2025

Assessing the impact of the particle drift effect on oral drug absorption using flux tools

Discover how particle drift analysis using flux tools improves oral drug absorption in pharmaceutical research.

From Pion Inc 31 Mar 2025

Biomanufacturing platform offers a sustainable alternative to synthesizing peptide-based pharmaceuticals

To tackle the inequity in medication access, a societal issue especially in developing nations, a team of undergraduate student-researchers at the University of Ottawa has developed a new biomanufacturing platform called Phytogene.

18 Mar 2025

Study demonstrates successful gene therapy for maple syrup urine disease

A study led by UMass Chan researchers demonstrated that a gene therapy to correct a mutation that causes maple syrup urine disease (MSUD) prevented newborn death, normalized growth, restored coordinated expression of the affected genes and stabilized biomarkers in a calf as well as in mice.

28 Feb 2025

Innovative combination of treatments effectively kills acute myeloid leukemia cells

Scientists at VCU Massey Comprehensive Cancer Center have identified an innovative combination of treatment strategies that work collaboratively to effectively kill acute myeloid leukemia (AML) cells, a frequently incurable form of cancer.

27 Feb 2025

Harbour BioMed partners with Insilico to accelerate AI-powered antibody discovery

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced a strategic collaboration to accelerate the discovery and development of innovative therapeutic antibodies, leveraging their respective technological strengths in antibody discovery and artificial intelligence.

21 Feb 2025